Stockreport

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update 

aTyr Pharma, Inc.  (ATYR) 
PDF Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarte [Read more]